Israel’s TA-25 Index (TA-25) rose for a fourth day, advancing 0.1 percent to 1,111.53, at the 4:30 p.m. close in Tel Aviv. The measure dropped 18 percent last year. Investors traded about 1.2 billion shekels ($311 million) of shares and convertible securities, according to bourse data.
The following stocks rose or fell today. Symbols are in parenthesis.
Biondvax Pharmaceuticals Ltd. (BNDX) , a developer of intra-nasal flu vaccines, soared the most since Sept. 7, advancing 6.6 percent to 1.69 shekels. Twelve people in five U.S. states have been infected with a new flu virus, according to the Centers for Disease Control and Prevention in Atlanta.
Elbit Imaging Ltd. (EMIT) surged to the highest level since Dec. 14, gaining 6.9 percent to 10.80 shekels. Calcalist reported that the investor in real estate and medical companies is in talks to sell its holdings in U.S. malls to Blackstone Group LP. A message left for a spokeswoman for Elbit Imaging wasn’t returned.
Delek Group Ltd. (DLEKG) gained the most since Dec. 20, climbing 2.5 percent to 725.80 shekels. The holding company was initiated with a “buy” recommendation at UBS AG.
D. Medical Industries Ltd. (DMED) (DMED IT) advanced 2.5 percent, the most since Nov. 30, to 5.27 shekels, giving the Tirat Carmel, Israel-based company a market value of 43 million shekels. The maker of drug-delivery devices said its infusion set was listed in a U.S. diabetes consumer guide.
Flowsense Medical Ltd. (FLSN) surged the most since Oct. 5, advancing 9.1 percent to 0.084 shekel. The maker of an automated urine-monitor system signed a memorandum of understanding with a U.S. distributor for the marketing of its URINFO 2000 system.
Space Communication Ltd. (SCC) gained 2.1 percent to 69.52 shekels, the highest since April 11. The supplier of satellite communication services said the Amos 5 satellite has reached its space slot.
Teva Pharmaceutical Industries Ltd. (TEVA) rose to the highest level since July 14, advancing 3.2 percent to 165.90 shekels, or the equivalent of $43.05. The shares of the world’s largest generic drugmaker advanced on reports Ranbaxy Laboratories Ltd. gained Lipitor market share and as analysts applauded the company’s choice of chief executive officer.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com